NAD+ dosage in the research: doses studied, routes, and clearance

The short version

This is a research digest, and it gives no NAD+ dosage instructions. Here is the landscape it describes. Almost all the controlled human data use precursors (building blocks like NR and NMN) taken by mouth, not NAD+ itself — because NAD+ is poorly absorbed intact. Oral NMN was studied around 250-900 mg/day; oral NR around 250-1000 mg/day, with 3000 mg/day tested only to check safety. IV NAD+ uses much larger infused amounts but has the weakest evidence. The numbers below are study doses, full stop — not recommendations.

Doses studied in the published research

These are the NAD+ dosage figures reported in human trials, presented as study doses with no recommendation attached. Oral NMN (a precursor) was studied at 250-900 mg/day; 250 mg/day is the most-replicated dose ^[6], and a multicenter trial compared 300, 600 and 900 mg/day, identifying 600 mg/day as optimal ^[3]. Oral NR (a precursor) was studied at 100-1000 mg/day for efficacy ^[4][14], with 3000 mg/day (1500 mg twice daily) tested for 30 days purely to establish a safety ceiling ^[9]. Nicotinamide (NAM) has been studied at 500 mg twice daily in a different context, skin-cancer chemoprevention.

IV NAD+ — the coenzyme itself, infused — is reported in wellness and clinical settings at roughly 250-1000 mg per session over several hours; one pharmacokinetic study used a continuous 3 µmol/min infusion over 6 hours. Historical addiction protocols used 500-1000 mg IV NAD+ daily over several days ^[8]. These IV figures rest on far weaker evidence than the oral-precursor trials.

Why most oral products are precursors, not NAD+ itself

Oral "NAD+" capsules face a basic absorption problem: NAD+ is a large, charged dinucleotide (663.43 Da) that is not freely taken up intact by most cells and is largely broken down before absorption ^[12]. In human skin fibroblasts, extracellular NAD was degraded by surface ecto-enzymes into nicotinamide, NMN and purine metabolites before any cellular uptake, with adenosine the principal product taken in ^[12]. That is why most experts consider precursors — NMN, NR, niacin/nicotinamide — the rational oral approach, and why oral NMN and NR, not oral NAD+, are the molecules with reproducible blood-NAD+ trial data ^[3][4].

How long does NAD+ persist? Clearance and precursor pharmacokinetics

The NAD+ half life question splits by route. Infused NAD+ itself is cleared from plasma rapidly — a pilot pharmacokinetic study found near-complete plasma removal within roughly the first two hours of infusion, because extracellular NAD is metabolized by ecto-enzymes before uptake ^[12]. So an IV bolus does not persist as circulating NAD+. Oral precursors behave differently: NR and NMN are absorbed and raise whole-blood NAD+ over days to weeks, with the elevation sustained through chronic dosing across 8-12 week trials ^[4][3]. The precursor route builds the pool gradually; the IV route spikes and clears.

Routes studied

Four route categories appear in the literature, with sharply different evidence weight. Oral (capsules or powder of NMN, NR or nicotinamide) carries the bulk of controlled human evidence ^[3][4][6]. Intravenous NAD+ infusion is used in wellness clinics with limited, mostly pilot or retrospective data ^[8]. Subcutaneous / intramuscular compounded NAD+ injection has minimal peer-reviewed pharmacokinetic data. Sublingual, intranasal, topical and transdermal patches are marketed but have little controlled evidence — no randomized trial in this digest supports patches or sprays raising NAD+. The oral-precursor route is where the data live.

Why the oral and IV dose figures are not comparable

It is tempting to line up an oral 1000 mg NR capsule against a 1000 mg IV NAD+ infusion as if they were the same dose of the same thing. They are not. The oral figures are precursor doses — NR or NMN — that the body converts into NAD+ along the salvage pipeline and that raise the pool gradually over days to weeks ^[3][4]. The IV figures are the coenzyme itself, pushed into plasma where it is rapidly degraded and cleared, much of it broken down extracellularly before any cell takes it up ^[12]. Same number on the label, entirely different molecule, route, and fate. The dose-response evidence — the part that is actually quantified and reproducible — lives almost entirely on the oral-precursor side ^[4].

Tolerability and reported adverse events in the trials

In the controlled oral-precursor trials, tolerability was good. NR at 100-1000 mg/day for 8 weeks showed no significant adverse-event difference from placebo and no flushing ^[4]. High-dose NR at 3000 mg/day for 30 days reported no moderate or severe adverse events and met its primary safety endpoint ^[9]. NMN at 250-900 mg/day reported no safety issues across trials ^[3][6].

The risk profile shifts by route. IV infusions can cause chest tightness, abdominal discomfort, flushing or nausea if run too fast ^[8]. Compounded injectable NAD+ has carried a Class I FDA recall for elevated bacterial endotoxin — the most serious recall class. A separate, theoretical concern is that boosting NAD+ could support the metabolism of existing cancers, since NAD+ fuels proliferating cells; its role in oncology is dual and context-dependent. None of this is medical advice — it is what the studies and recalls report.